Apr 24, 2024 • 4:05 pm EDT Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Apr 2, 2024 • 8:00 am EDT Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Mar 12, 2024 • 8:00 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Mar 6, 2024 • 8:00 am EST Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
Feb 28, 2024 • 8:00 am EST Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
Feb 6, 2024 • 9:50 am EST Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Feb 2, 2024 • 4:01 pm EST Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 26, 2024 • 7:30 am EST CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024